Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

2010888 citationsJournal Articlebronze Open Access

Authors

Gregg W. Stone · NewYork–Presbyterian Hospital

Ali A. Rizvi

William Newman · WakeMed

Kourosh Mastali · St. Joseph Medical Center

John Wang · MedStar Union Memorial Hospital

Ronald Caputo · St Joseph's Hospital Health Center

Julie Doostzadeh · Abbott (United States)

Abstract

Everolimus-eluting stents, as compared with paclitaxel-eluting stents, resulted in reduced rates of target-lesion failure at 1 year, results that were consistent in all patients except those with diabetes, in whom the results were nonsignificantly different. (ClinicalTrials.gov number, NCT00307047.)

Topics & Keywords

Coronary Interventions and Diagnostics Cardiac Imaging and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 18, pp. 1663-1674

DOI: 10.1056/nejmoa0910496

Field-Weighted Citation Impact: 109.74